false Q2 --12-31 0001859007 No No 0001859007 2025-01-01 2025-06-30 0001859007 2025-08-07 0001859007 2025-06-30 0001859007 2024-12-31 0001859007 us-gaap:SeriesAPreferredStockMember 2025-06-30 0001859007 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001859007 us-gaap:SeriesBPreferredStockMember 2025-06-30 0001859007 us-gaap:SeriesBPreferredStockMember 2024-12-31 0001859007 2025-04-01 2025-06-30 0001859007 2024-04-01 2024-06-30 0001859007 2024-01-01 2024-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-12-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-12-31 0001859007 us-gaap:CommonStockMember 2024-12-31 0001859007 ZVSA:TreasuryCommonAndPreferredStockMember 2024-12-31 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001859007 us-gaap:RetainedEarningsMember 2024-12-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-03-31 0001859007 us-gaap:CommonStockMember 2025-03-31 0001859007 ZVSA:TreasuryCommonAndPreferredStockMember 2025-03-31 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001859007 us-gaap:RetainedEarningsMember 2025-03-31 0001859007 2025-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-12-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001859007 us-gaap:CommonStockMember 2023-12-31 0001859007 ZVSA:TreasuryCommonAndPreferredStockMember 2023-12-31 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001859007 us-gaap:RetainedEarningsMember 2023-12-31 0001859007 2023-12-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-03-31 0001859007 us-gaap:CommonStockMember 2024-03-31 0001859007 ZVSA:TreasuryCommonAndPreferredStockMember 2024-03-31 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001859007 us-gaap:RetainedEarningsMember 2024-03-31 0001859007 2024-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-01-01 2025-03-31 0001859007 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001859007 ZVSA:TreasuryCommonAndPreferredStockMember 2025-01-01 2025-03-31 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001859007 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001859007 2025-01-01 2025-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-04-01 2025-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-04-01 2025-06-30 0001859007 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001859007 ZVSA:TreasuryCommonAndPreferredStockMember 2025-04-01 2025-06-30 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001859007 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-03-31 0001859007 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001859007 ZVSA:TreasuryCommonAndPreferredStockMember 2024-01-01 2024-03-31 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001859007 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001859007 2024-01-01 2024-03-31 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-04-01 2024-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-06-30 0001859007 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001859007 ZVSA:TreasuryCommonAndPreferredStockMember 2024-04-01 2024-06-30 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001859007 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-06-30 0001859007 us-gaap:CommonStockMember 2025-06-30 0001859007 ZVSA:TreasuryCommonAndPreferredStockMember 2025-06-30 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001859007 us-gaap:RetainedEarningsMember 2025-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-06-30 0001859007 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-06-30 0001859007 us-gaap:CommonStockMember 2024-06-30 0001859007 ZVSA:TreasuryCommonAndPreferredStockMember 2024-06-30 0001859007 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001859007 us-gaap:RetainedEarningsMember 2024-06-30 0001859007 2024-06-30 0001859007 2024-04-25 2024-04-25 0001859007 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001859007 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001859007 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001859007 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001859007 ZVSA:SeriesAConvertiblePreferredStockMember 2025-01-01 2025-06-30 0001859007 ZVSA:SeriesAConvertiblePreferredStockMember 2024-01-01 2024-06-30 0001859007 ZVSA:SeriesBConvertiblePreferredStockMember 2025-01-01 2025-06-30 0001859007 ZVSA:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-06-30 0001859007 ZVSA:InflamacoreLlcLicenseAgreementMember 2025-06-30 0001859007 ZVSA:InflamacoreLlcLicenseAgreementMember 2024-06-30 0001859007 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember ZVSA:OneVendorMember 2025-01-01 2025-06-30 0001859007 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember ZVSA:OneVendorMember 2024-01-01 2024-12-31 0001859007 us-gaap:SubsequentEventMember 2025-07-04 2025-07-04 0001859007 2024-06-30 2024-06-30 0001859007 2024-07-01 2024-07-01 0001859007 ZVSA:AccruedExpensesAndOtherCurrentLiabilitiesMember 2025-06-30 0001859007 2019-01-18 0001859007 2019-01-18 2019-01-18 0001859007 ZVSA:LeaseCommitmentMember 2024-01-15 2024-01-15 0001859007 ZVSA:LeaseCommitmentMember 2025-01-09 2025-01-09 0001859007 ZVSA:MarketingAgreementsMember us-gaap:CommonStockMember 2025-02-02 2025-02-02 0001859007 ZVSA:MarketingAgreementsMember us-gaap:CommonStockMember 2025-02-02 0001859007 ZVSA:MarketingAgreementsMember us-gaap:CommonStockMember 2025-03-20 2025-03-20 0001859007 ZVSA:MarketingAgreementsMember us-gaap:CommonStockMember 2025-03-20 0001859007 us-gaap:CommonStockMember ZVSA:MarketingAgreementsMember 2025-04-11 0001859007 ZVSA:MarketingAgreementsMember us-gaap:CommonStockMember 2025-05-01 2025-05-01 0001859007 ZVSA:MarketingAgreementsMember us-gaap:CommonStockMember 2025-05-01 0001859007 us-gaap:CommonStockMember ZVSA:MarketingAgreementsMember 2025-05-13 0001859007 ZVSA:ELOCSharesMember ZVSA:EquityPurchaseAgreementMember 2025-06-24 2025-06-24 0001859007 2025-06-24 2025-06-24 0001859007 us-gaap:WarrantMember 2025-06-24 0001859007 2025-06-24 0001859007 us-gaap:ResearchAndDevelopmentExpenseMember 2025-04-01 2025-06-30 0001859007 us-gaap:GeneralAndAdministrativeExpenseMember 2025-04-01 2025-06-30 0001859007 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001859007 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001859007 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-06-30 0001859007 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-06-30 0001859007 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001859007 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001859007 ZVSA:March2025PreFundedWarrantsMember us-gaap:PrivatePlacementMember 2025-03-07 0001859007 ZVSA:March2025CommonWarrantsMember us-gaap:PrivatePlacementMember 2025-03-07 0001859007 us-gaap:PrivatePlacementMember ZVSA:March2025CommonWarrantsAndPrefundedWarrantsMember 2025-03-07 0001859007 us-gaap:PrivatePlacementMember ZVSA:March2025CommonWarrantsAndPrefundedWarrantsMember 2025-03-07 2025-03-07 0001859007 us-gaap:PrivatePlacementMember ZVSA:March2025CommonWarrantsAndPrefundedWarrantsMember 2024-11-05 0001859007 us-gaap:PrivatePlacementMember ZVSA:March2025CommonWarrantsAndPrefundedWarrantsMember 2024-11-04 0001859007 us-gaap:PrivatePlacementMember ZVSA:March2025PreFundedWarrantsMember 2025-01-01 2025-06-30 0001859007 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceOneMember 2025-06-30 0001859007 ZVSA:ExercisePriceOneMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceTwoMember 2025-06-30 0001859007 ZVSA:ExercisePriceTwoMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceThreeMember 2025-06-30 0001859007 ZVSA:ExercisePriceThreeMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceFourMember 2025-06-30 0001859007 ZVSA:ExercisePriceFourMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceFiveMember 2025-06-30 0001859007 ZVSA:ExercisePriceFiveMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceSixMember 2025-06-30 0001859007 ZVSA:ExercisePriceSixMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceSevenMember 2025-06-30 0001859007 ZVSA:ExercisePriceSevenMember 2025-01-01 2025-06-30 0001859007 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001859007 ZVSA:March2025PreFundedWarrantsMember 2025-06-30 0001859007 ZVSA:November2024WarrantsMember 2025-01-01 2025-06-30 0001859007 ZVSA:November2024WarrantsMember srt:MaximumMember 2025-01-01 2025-06-30 0001859007 ZVSA:November2024WarrantsMember srt:MinimumMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceOneMember us-gaap:WarrantMember 2025-06-30 0001859007 ZVSA:ExercisePriceOneMember us-gaap:WarrantMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceTwoMember us-gaap:WarrantMember 2025-06-30 0001859007 ZVSA:ExercisePriceTwoMember us-gaap:WarrantMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceThreeMember us-gaap:WarrantMember 2025-06-30 0001859007 ZVSA:ExercisePriceThreeMember us-gaap:WarrantMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceFourMember us-gaap:WarrantMember 2025-06-30 0001859007 ZVSA:ExercisePriceFourMember us-gaap:WarrantMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceFiveMember us-gaap:WarrantMember 2025-06-30 0001859007 ZVSA:ExercisePriceFiveMember us-gaap:WarrantMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceSixMember us-gaap:WarrantMember 2025-06-30 0001859007 ZVSA:ExercisePriceSixMember us-gaap:WarrantMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceSevenMember us-gaap:WarrantMember 2025-06-30 0001859007 ZVSA:ExercisePriceSevenMember us-gaap:WarrantMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceEightMember us-gaap:WarrantMember 2025-06-30 0001859007 ZVSA:ExercisePriceNineMember us-gaap:WarrantMember 2025-06-30 0001859007 ZVSA:ExercisePriceNineMember us-gaap:WarrantMember 2025-01-01 2025-06-30 0001859007 ZVSA:ExercisePriceTenMember us-gaap:WarrantMember 2025-06-30 0001859007 ZVSA:ExercisePriceTenMember us-gaap:WarrantMember 2025-01-01 2025-06-30 0001859007 us-gaap:WarrantMember 2025-06-30 0001859007 us-gaap:SubsequentEventMember ZVSA:SeriesA2CommonStockMember 2025-07-08 0001859007 us-gaap:SubsequentEventMember ZVSA:SeriesA3CommonStockMember 2025-07-08 0001859007 us-gaap:SubsequentEventMember 2025-07-08 0001859007 us-gaap:SubsequentEventMember ZVSA:InducementWarrantsMember 2025-07-08 2025-07-08 0001859007 us-gaap:SubsequentEventMember ZVSA:InducementWarrantsMember 2025-07-08 0001859007 us-gaap:SubsequentEventMember ZVSA:InducementWarrantsMember ZVSA:SeriesA4CommonStockMember 2025-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft ZVSA:Segment

 

 

 

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

WASHINGTON,D.C. 20549

 

FORM10-Q

 

(MarkOne)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Forthe quarterly period ended June 30, 2025

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Forthe transition period from _________to_________

 

CommissionFile Number: 001-41184

 

ZYVERSATHERAPEUTICS, INC.

(Exactname of registrant as specified in its charter)

 

Delaware   86-2685744

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

     

2200 N. Commerce Parkway, Suite 208

Weston, FL 33326

 

 

33326

(Address of principal executive offices)   (Zip Code)
     
(754) 231-1688
(Registrant’s telephone number, including area code)

 

Securitiesregistered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   ZVSA   The Nasdaq Capital Market (1)

 

Indicateby check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days. Yes: ☒ No: ☐

 

Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrantwas required to submit such files). Yes: ☒ No: ☐

 

Indicateby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicateby check mark if the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: ☐ No:

 

Asof August 7, 2025, the number of shares outstanding of the registrant’s common stock, $0.0001 par value per share, was 8,095,921.

 

(1) As of July 17, 2025, our common stock has been suspended fromtrading on The Nasdaq Capital Market. Our common stock is quoted on the OTCQB® Venture Market under the symbol “ZVSA.”

 

 

 

 

 

 

ZYVERSATHERAPEUTICS, INC.

INDEXTO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

PART I - FINANCIAL INFORMATION 1
   
Item 1. Financial Statements. 1
   
Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 1
   
Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 2
   
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2025 and 2024 3
   
Unaudited Condensed Consolidated Statements of Cash Flows for the Three and Six Months Ended June 30, 2025 and 2024 4
   
Notes to Unaudited Condensed Consolidated Financial Statements 5
   
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 11
   
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk. 17
   
ITEM 4. Controls and Procedures. 17
   
PART II - OTHER INFORMATION 18
   
ITEM 1. Legal Proceedings. 18
   
ITEM 1A. Risk Factors. 18
   
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds. 18
   
ITEM 3. Defaults Upon Senior Securities. 18
   
ITEM 4. Mine Safety Disclosures. 18
   
ITEM 5. Other Information. 18
   
ITEM 6. Exhibits. 19
   
SIGNATURES 20

 

i

 

 

PARTI FINANCIAL INFORMATION

 

Item1. Financial Statements

 

ZYVERSATHERAPEUTICS, INC.

 

CONDENSEDCONSOLIDATED BALANCE SHEETS

 

   June 30,   December 31, 
   2025   2024 
    (Unaudited)       
Assets          
           
Current Assets:          
Cash  $72,086   $1,530,924 
Prepaid expenses and other current assets   378,749    184,873 
Vendor deposits   98,234    - 
Total Current Assets   549,069    1,715,797 
           
In-process research and development   18,647,903    18,647,903 
Vendor deposit   69,477    178,476 
Deferred offering costs   374,662    57,238 
           
Total Assets  $19,641,111   $20,599,414 
           
Liabilities and Stockholders’ Equity          
           
Current Liabilities:          
Accounts payable  $9,774,230   $9,337,267 
Accrued expenses and other current liabilities   2,915,448    1,894,041 
Total Current Liabilities   12,689,678    11,231,308 
Deferred tax liability   851,659    851,659 
Total Liabilities   13,541,337    12,082,967 
           
Commitments and contingencies (Note 6)   -    - 
           
Stockholders’ Equity:          
Preferred stock, $0.0001 par value, 1,000,000 shares authorized:          
Series A preferred stock, 8,635 shares designated, 50 shares issued and outstanding as of June 30, 2025 and December 31, 2024   -    - 
Series B preferred stock, 5,062 shares designated, 5,062 shares issued and outstanding as of June 30, 2025 and December 31, 2024   1    1 
Common stock, $0.0001 par value, 250,000,000 shares authorized; 4,873,463 and 2,508,198 shares issued as of June 30, 2025 and December 31, 2024, respectively, and 4,873,456 and 2,508,191 shares outstanding as of June 30, 2025 and December 31, 2024, respectively   487    251 
Additional paid-in-capital   123,207,260    121,155,922 
Accumulated deficit   (117,100,806)   (112,632,559)
Treasury stock, at cost, 7 shares at June 30, 2025 and December 31, 2024,   (7,168)   (7,168)
Total Stockholders’ Equity   6,099,774    8,516,447 
           
Total Liabilities and Stockholders’ Equity  $19,641,111   $20,599,414 

 

Theaccompanying notes are an integral part of these condensed consolidated financial statements.

 

1

 

 

ZYVERSATHERAPEUTICS, INC.

 

CONDENSEDCONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   2025   2024   2025   2024 
   For the Three Months Ended
June 30,
   For the Six Months Ended
June 30,
 
   2025   2024   2025   2024 
Operating Expenses:                    
Research and development  $409,937   $709,049   $668,813   $1,221,987 
General and administrative   1,634,195    2,044,929    3,519,889    4,358,627 
Total Operating Expenses   2,044,132    2,753,978    4,188,702    5,580,614 
                     
Loss From Operations   (2,044,132)   (2,753,978)   (4,188,702)   (5,580,614)
                     
Other (Income) Expense:                    
Interest expense   130,036    58    249,596    159 
Change in fair value of equity payable   37,149    -    29,949    - 
                     
Pre-Tax Net Loss   (2,211,317)   (2,754,036)   (4,468,247)   (5,580,773)
Income tax benefit   -    (9,707)   -    (9,707)
Net Loss  $(2,211,317)  $(2,763,743)  $(4,468,247)  $(5,590,480)
                     
Net Loss Per Share                    
- Basic and Diluted  $(0.46)  $(3.31)  $(1.13)  $(7.67)
                     
Weighted Average Number of Common Shares Outstanding                    
- Basic and Diluted   4,814,115    834,915    3,965,236    729,306 

 

Theaccompanying notes are an integral part of these condensed consolidated financial statements.

 

2

 

 

ZYVERSATHERAPEUTICS, INC.

 

CONDENSEDCONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

 

ForThe Three and Six Months Ended June 30, 2025 and 2024

(Unaudited)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
   For the Three and Six Months Ended June 30, 2025 
   Series A   Series B                   Additional       Total 
   Preferred Stock   Preferred Stock   Common Stock   Treasury Stock   Paid-In   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
                                             
Balance - December 31, 2024   50   $      -    5,062  $       1    2,508,198   $251    (7)  $(7,168)  $121,155,922   $(112,632,559)  $   8,516,447 
                                                     - 
Issuance of common stock pursuant to vendor agreements   -    -    -    -    60,000    6    -    -    81,594    -    81,600 
Private placement of warrants [1]   -    -    -    -    -    -    -    -    1,663,052    -    1,663,052 
Warrant modification   -    -    -    -    -    -    -    -    53,890    -    53,890 
Stock-based compensation   -    -    -    -    -    -    -    -    72,291    -    72,291 
Net loss   -    -    -    -    -    -    -    -    -    (2,256,930)   (2,256,930)
Balance - March 31, 2025   50    -    5,062    1    2,568,198    257    (7)   (7,168)   123,026,749    (114,889,489)   8,130,350 
                                                        
Issuance of common stock pursuant to vendor agreements   -    -    -    -    200,000    20    -    -    128,780    -    128,800 
Exercise of pre-funded warrants   -    -    -    -    2,105,265    210    -    -    -    -    210 
Private placement of warrants additional offering costs   -    -    -    -    -    -    -    -    (7,468)   -    (7,468)
Stock-based compensation   -    -    -    -    -    -    -    -    59,199    -    59,199 
Net loss   -    -    -    -    -    -    -    -    -    (2,211,317)   (2,211,317)
Balance - June 30, 2025   50   $-    5,062   $1    4,873,463   $487    (7)  $(7,168)  $123,207,260   $(117,100,806)  $6,099,774 

 

   For the Three and Six Months Ended June 30, 2024 
   Series A   Series B                   Additional       Total 
   Preferred Stock   Preferred Stock   Common Stock   Treasury Stock   Paid-In   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
                                             
Balance - December 31, 2023   50   $      -    5,062   $       1    405,212   $40    (7)  $(7,168)  $114,300,849   $(103,219,124)  $  11,074,598 
                                                        
Exercise of warrants   -    -    -    -    213,800    21    -    -    2,672,479    -    2,672,500 
Exercise of pre-funded warrants   -    -    -    -    131,481    13    -    -    (13)   -    - 
Issuance of common stock pursuant to vendor agreements   -    -    -    -    9,000    1    -    -    79,199    -    79,200 
Round up share adjustment due to reverse split   -    -    -    -    75,410    8    -    -    (8)   -    - 
Stock-based compensation   -    -    -    -    -    -    -    -    223,573    -    223,573 
Net loss   -    -    -    -    -    -    -    -    -    (2,826,737)   (2,826,737)
Balance - March 31, 2024   50    -    5,062    1    834,903    83    (7)   (7,168)   117,276,079    (106,045,861)   11,223,134 
                                                        
Stock-based compensation   -    -    -    -    -    -    -    -    160,664    -    160,664 
Net loss   -    -    -    -    -    -    -    -    -    (2,763,743)   (2,763,743)
Balance - June 30, 2024   50   $-    5,062   $1    834,903   $83    (7)  $(7,168)  $117,436,743   $(108,809,604)  $8,620,055 

 

[1]Includes gross proceeds of $1,999,791 less cash issuance costs of $282,849 and a non-cashwarrant modification charge of $53,890

 

Theaccompanying notes are an integral part of these condensed consolidated financial statements.

 

3

 

 

ZYVERSATHERAPEUTICS, INC.

 

CONDENSEDCONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   2025   2024 
   For the Six Months Ended June 30, 
   2025   2024 
         
Cash Flows From Operating Activities:          
Net loss  $(4,468,247)  $(5,590,480)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock- based compensation   131,490    384,237 
Issuance of common stock pursuant to vendor agreements   210,400    79,200 
Depreciation of fixed assets   -    5,200 
Non-cash rent expense   -    7,839 
Deferred tax provision   -    9,707 
Changes in operating assets and liabilities:          
Prepaid expenses and other current assets   (193,876)   (306,447)
Accounts payable   

56,208

    (115,077)
Vendor deposits   8,700    (80,000)
Operating lease liability   -    (8,656)
Accrued expenses and other current liabilities   

961,545

    (76,211)
           
NetCash Used In Operating Activities   (3,293,780)   (5,690,688)
           
Cash Flows From Financing Activities:          
Exercise of warrants   -    2,672,500 
Private placement of warrants   1,999,791    - 
Exercise of pre-funded warrants   210    - 
Deferred offering costs   (17,928)   - 
Registration and issuance costs associated with warrant issuance   (147,131)   - 
          
NetCash Provided By Financing Activities   1,834,942    2,672,500 
           
Net Decrease in Cash   (1,458,838)   (3,018,188)
           
Cash - Beginning of Period   1,530,924    3,137,674 
           
Cash - End of Period  $72,086   $119,486 
           
Supplemental Disclosures of Cash Flow Information:          
Warrant modification - incremental value  $53,890   $- 
Accounts payable and accrued expenses for offering costs  $459,696   $- 

 

Theaccompanying notes are an integral part of these condensed consolidated financial statements.

 

4

 

 

ZYVERSATHERAPEUTICS, INC.

 

Notesto Condensed Consolidated Financial Statements

 

Note1 – Business Organization, Nature of Operations and Basis of Presentation

 

Organizationand Operations

 

ZyVersaTherapeutics, Inc. (“ZyVersa” and the “Company”) is a clinical stage biopharmaceutical company leveraging proprietarytechnologies to develop first-in-class drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs.The Company’s mission is to develop drugs that optimize health outcomes and improve patients’ quality of life.

 

Basisof Presentation and Principles of Consolidation

 

Theaccompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generallyaccepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not includeall of the information and disclosures required by accounting principles generally accepted in the United States of America for annualfinancial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items)which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company asof June 30, 2025 and for the three and six months ended June 30, 2025 and 2024. The results of operations for the six months ended June30, 2025 are not necessarily indicative of the operating results for the full year. It is suggested that these unaudited condensed consolidatedfinancial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’sannual report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”)on March 27, 2025.

 

OnApril 25, 2024, the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”).Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one shareof common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertiblesecurities and warrants were proportionally decreased, and the corresponding conversion price or exercise price was proportionally increased.No fractional shares were issued as a result of the 2024 Reverse Split.

 

Accordingly,all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively,where applicable, to reflect the 2024 Reverse Split and adjustment of the conversion price or exercise price of each outstanding equityaward, convertible security and warrant as if the transaction had occurred as of the beginning of the earliest period presented.

 

Note2 - Going Concern and Management’s Plans

 

Theaccompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realizationof assets and the satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do notinclude any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities thatmight be necessary should the Company be unable to continue as a going concern.

 

Asof June 30, 2025, the Company had cash of approximately $72.1 thousand and a working capital deficit of approximately $12.1 million.During the six months ended June 30, 2025, the Company incurred a net loss of approximately $4.5 million and used cash in operationsof approximately $3.3 million. The Company has an accumulated deficit of approximately $117.1 million as of June 30, 2025.

 

TheCompany has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its researchand development and general and administrative expenses will continue to increase and, as a result, the Company will eventually needto generate significant product revenues to achieve profitability.

 

Consequently,the Company will be required to raise additional funds through equity or debt financing. Management believes that the Company has accessto capital resources and continues to evaluate additional financing opportunities; however, there can be no assurance that it will besuccessful in securing additional capital or that the Company will be able to obtain funds on commercially acceptable terms, if at all.There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its development initiativesor attain profitable operations. The aforementioned conditions raise substantial doubt about the Company’s ability to continueas a going concern for at least one year from the issuance date of these financial statements.

 

Note3 – Summary of Significant Accounting Policies

 

Sincethe date the Company’s December 31, 2024 financial statements were issued in its 2024 Annual Report on Form 10-K, there have beenno material changes to the Company’s significant accounting policies.

 

5

 

 

ZYVERSATHERAPEUTICS, INC.

 

Notesto Condensed Consolidated Financial Statements

 

Useof Estimates

 

Preparationof financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect theamounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Companybases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under thecircumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reportedfor each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculationsfor equity securities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances fordeferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to theCompany and general economic conditions. It is reasonably possible that actual results could differ from those estimates.

 

NetLoss Per Common Share

 

Basicnet loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding duringthe period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutivecommon-equivalent shares outstanding during each period.

 

Thefollowing table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted netloss per share because to do so would be anti-dilutive:

   2025   2024 
   As of June 30, 
   2025   2024 
Warrants [1]   3,849,308    689,293 
Options   9,460    9,671 
Series A Convertible Preferred Stock   72    72 
Series B Convertible Preferred Stock   2,067    2,067 
Total potentially dilutive shares   3,860,907    701,103 

 

[1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported.

 

SegmentReporting

 

TheCompany has one operating and reporting segment (clinical stage biopharmaceutical), namely, the development of drugs for patients withchronic renal or inflammatory diseases with high unmet medical needs. The accounting policies of the segment are the same as those describedin the summary of significant accounting policies. The chief operating decision maker (“CODM”), who is the Company’schief executive officer, utilizes the Company’s financial information on an aggregate, consolidated basis for purposes of makingoperating decisions, allocating resources and assessing financial performance, as well as for making strategic operations decisions andmanaging the organization. The CODM is not regularly provided with disaggregated actual expense information, other than the actual expenseinformation included in the condensed consolidated statements of operations. The measure of segment assets is reported on the balancesheet as total assets. The Company has not yet generated any revenue from product sales.

 

VendorConcentration

 

Asof June 30, 2025 and December 31, 2024, accounts payable to one vendor accounted for 56% and 56%, respectively, related to research anddevelopment. The Company relies on this vendor to perform critical research and development.

 

RecentlyIssued Accounting Pronouncements

 

InDecember 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in thisupdate address investor requests for more transparency about income tax information through improvements to income tax disclosures primarilyrelated to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve theeffectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024,with early adoption permitted. The Company is currently evaluating the impact of this standard but does not expect it to have a materialimpact on its financial statements.

 

InNovember 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures(Subtopic 220 – 04). This update requires an entity to disclose more detailed information regarding expenses for the entity. Theamendments require that at each interim and the annual reporting period, the entity must disclose amounts related to purchases of inventory,employee compensation, depreciation, and intangible asset amortization. Including the amounts, the entity is required to disclose andqualitative description of the amounts remaining in relevant expense captions, and to disclose the total amount of selling expenses andthe definition of selling expenses. The amendments in this update should be applied prospectively to financial statements issued forreporting periods, and retrospectively to any prior periods presented in the financials. Although early adoption is permitted, the newguidance becomes effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning afterDecember 15, 2027. Since this new ASU addresses only disclosures, the Company does not expect the adoption of this ASU to have any materialeffects on its financial condition, results of operations or cash flows.

 

6

 

 

ZYVERSATHERAPEUTICS, INC.

 

Notesto Condensed Consolidated Financial Statements

 

Note4 – Accrued Expenses and Other Current Liabilities

 

Accruedexpenses and other current liabilities consisted of the following as of June 30, 2025 and December 31, 2024:

   June 30,   December 31, 
   2025   2024 
         
Payroll accrual  $1,101,584   $1,039,338 
Bonus accrual   917,375    536,500 
Interest accrual   518,390    268,972 
Accrued issuable equity   289,006    - 
Other accrued expenses   81,832    41,970 
Registration delay liability   7,261    7,261 
Total accrued expenses and other current liabilities  $2,915,448   $1,894,041 

 

Note5 – Income Taxes

 

Thetax provisions for the three and six months ended June 30, 2025 and 2024 were computed using the estimated effective tax rates applicableto the taxable jurisdictions for the full year. The Company’s tax rate is subject to management’s quarterly review and revision,as necessary. The Company’s effective tax rate was 0.00% and 0.00% for the three and six months ended June 30, 2025 and 2024, becausethe Company has significant net deferred tax assets, including those associated with net operating losses, that are subject to a fullvaluation allowance.

 

TaxLaw Change

 

OnJuly 4, 2025, the President signed into law significant federal tax legislation, H.R.1 (the “Tax Reform Act of 2025”).The legislation includes numerous changes to U.S. corporate income tax law, including but not limited to: permanent 100% bonus depreciationfor qualified property, immediate expensing of domestic research and experimental expenditures, modifications to the limitation on businessinterest expense, increased Section 179 expensing limits, changes to the international tax regime, and expanded limitations on the deductibilityof executive compensation under IRC Section 162(m). Most provisions are effective for tax years beginning after December 31, 2024, withcertain transition rules and exceptions.

 

TheCompany is currently evaluating the impact of the Tax Reform Act of 2025 on its condensed consolidated financial statements. FASB ASC 740, “Income Taxes,” requires the effects of changes in tax rates and laws on tax balances tobe recognized in the period in which the legislation is enacted. As the date of enactment of the Tax Reform Act of 2025 is after June30, 2025, there is no financial impact as of and for the six-moth period ended June 30, 2025. The effectsof the new law, including remeasurement of deferred tax assets and liabilities and changes to current and future tax expense, will bereflected in future periods.

 

Note6 – Commitments and Contingencies

 

Litigations,Claims and Assessments

 

TheCompany may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company recordscontingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonablyestimable.

 

DisputedVendor Invoices

 

OnJune 30, 2024 and July 1, 2024, the Company received two invoices from a vendor in the amounts of $992,176 and $162,800, respectively.The June 30, 2024 invoice represents retroactive interest on invoices going back to September 30, 2022. The July 1, 2024 invoice includedmiscellaneous unsupported charges performed over the past several years. On August 1, 2024, ZyVersa management sent the vendor a letterdisputing the interest and unsupported charges and has requested the vendor to rescind each of them. Although the Company has requestedthe vendor to rescind the retroactive interest on invoices, the Company believes that, in accordance with the agreement, the vendor canlegally charge the Company interest from the point they were notified of the vendor’s intent to charge interest. As such, the Companyincluded the calculated interest from July 1, 2024 to June 30, 2025 of $518,390 within accrued expenses and other current liabilitieson the condensed consolidated balance sheet at June 30, 2025. The vendor also updated certain interest calculations such that, at June30, 2025, the vendors claim that has not been accrued by the Company is $1,123,973.

 

OperatingLeases

 

OnJanuary 18, 2019, the Company entered into a lease agreement for approximately 3,500 square feet of office space in Weston, Florida fora term of five years. Under the lease agreement, the annual base rent, which excludes the Company’s share of taxes and operatingcosts, was approximately $89,000 for the first year and has increased approximately 3% every year thereafter for a total base rent leasecommitment of approximately $497,000. On January 15, 2024, the Company extended the lease for an additional year for a total base rentlease commitment of $112,064. On January 9, 2025, the Company extended the lease for an additional year for a total base rent lease commitmentof approximately $120,819. The Company used the short-term lease practical expedient which permits the Company to not capitalize leaseswith a term equal to or less than 12 months.

 

7

 

 

ZYVERSATHERAPEUTICS, INC.

 

Notesto Condensed Consolidated Financial Statements

 

TheCompany recognized rent expense in connection with its operating lease for the three months ended June 30, 2025 and 2024 of $45,168 and$43,271, respectively.

 

TheCompany recognized rent expense in connection with its operating lease for the six months ended June 30, 2025 and 2024 of $89,364 and$84,743, respectively.

 

Note7 – Stockholders’ Equity

 

CommonStock

 

OnFebruary 2, 2025, the Company entered into a marketing agreement with a vendor in which the Company issued 60,000 shares of common stockand cash in exchange for marketing services. The fair value of the common stock was established as a prepaid expense, and the Companyrecognized $81,600 of the expense over the two-month term of the contract. The shares were issued on February 2, 2025.

 

OnMarch 20, 2025, the Company entered into a marketing agreement with a vendor in which the Company issued 100,000 shares of common stockand cash in exchange for digital marketing services. The fair value of the common stock was established as a prepaid expense and theCompany recognized $70,100 of the expense over the three-month term of the contract. On April 11, 2025, the Company issued the 100,000shares of common stock to the vendor using the market value of $77,000 on that date.

 

OnMay 1, 2025, the Company entered into a marketing agreement with a vendor in which the Company issued 100,000 shares of common stockand cash in exchange for marketing services. The fair value of the common stock was established as a prepaid expense and the Companyrecognized $61,900 of the expense over the two-month term of the contract. On May 13, 2025, the Company issued the 100,000 shares ofcommon stock to the vendor using the market value of $51,800 on that date.

 

EquityPurchase Agreement

 

OnJune 24, 2025, the Company entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Williamsburg VentureHoldings, LLC (the “Purchaser”), whereby the Company has the right, but not the obligation, to sell to the Purchaser, andthe Purchaser is obligated to purchase, up to an aggregate of $10.0 million of shares (the “ELOC Shares”) of the Company’scommon stock. The term of the Purchase Agreement is through June 24, 2027, or the date on which the Purchaser has purchased ELOC Sharesfor an aggregate purchase price of $10.0 million. The Company has also agreed to issue to the Purchaser426,829 shares common stock (“Commitment Shares”), which will be issued on a pro rata basis as the Company draws down ELOCshares, with any remaining shares to be issued upon termination. The fair value of the Commitment Shares on the date of the PurchaseAgreement was established as accrued issuable equity and as deferred offering costs and the Company will reclassify $265,957 of the deferredoffering costs to additional paid-in-capital on a pro rata basis as the Company draws down ELOC shares. In addition, the Company willmark-to-market the change in fair value of the accrued issuable equity on each reporting date.

 

Stock-BasedCompensation

 

Forthe three months ended June 30, 2025 the Company recorded stock-based compensation expense of $59,199 (of which, $15,448 was includedin research and development and $43,751 was included in general and administrative expense) related to options issued to employees andconsultants. For the three months ended June 30, 2024 the Company recorded stock-based compensation expense of $160,664 (of which, $15,447was included in research and development and $145,217 was included in general and administrative expense) related to options issued toemployees and consultants.

 

Forthe six months ended June 30, 2025 the Company recorded stock-based compensation expense of $131,490 (of which, $30,895 was includedin research and development and $100,595 was included in general and administrative expense) related to options issued to employees andconsultants. For the six months ended June 30, 2024 the Company recorded stock-based compensation expense of $384,237 (of which, $30,895was included in research and development and $353,342 was included in general and administrative expense) related to options issued toemployees and consultants. As of June 30, 2025 there was $190,403 of unrecognized stock-based compensation expense, which the Companyexpects to recognize over a weighted average period of 0.8 years

 

StockOptions

 

Asummary of the option activity for the six months ended June 30, 2025 is presented below:

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Options   Price   In Years   Value 
                 
Outstanding, January 1, 2025   9,612   $2,248.58                
Granted   -    -           
Exercised   -    -           
Expired   (152)   1,760.50           
Outstanding, June 30, 2025   9,460   $2,222.82    5.8   $- 
                     
Exercisable, June 30, 2025   8,112   $2,598.23    5.5   $- 

 

8

 

 

ZYVERSATHERAPEUTICS, INC.

 

Notesto Condensed Consolidated Financial Statements

 

Thefollowing table presents information related to stock options as of June 30, 2025:

Options Outstanding   Options Exercisable 
        Weighted     
    Outstanding   Average   Exercisable 
Exercise   Number of   Remaining Life   Number of 
Price   Options   In Years   Options 
$152.50    4,157    7.9    2,916 
$738.50    286    7.6    191 
$791.00    38    7.7    26 
$1,760.50    1,127    1.6    1,127 
$3,965.50    37    7.0    37 
$4,053.00    2,095    3.8    2,095 
$5,726.00    1,720    6.0    1,720 
      9,460    5.5    8,112 

 

StockWarrants

 

OnMarch 7, 2025, the Company closed on a private placement (the “Private Placement”) with an institutional investor,pursuant to which the Company sold pre-funded warrants (the “March 2025 Pre-Funded Warrants”) to purchase 2,105,265shares of common stock and Series A-3 common warrants (the “March 2025 Common Warrants”) to purchase 2,105,265shares of common stock at a combined purchase price of $0.9499which resulted in gross proceeds of approximately $2.0million. In addition, the Company and the investor executed an amendment to certain November 5, 2024 common share purchase warrantsto reduce the exercise price of certain outstanding warrants to purchase 957,200shares of common stock from $2.06per share to $1.00per share. The $53,890incremental fair value of the modified warrants as compared to the original warrants was recognized as an additional issuance costof the Private Placement. The March 2025 Pre-Funded Warrants were exercisable immediately at an exercise price of $0.0001per share. As of June 30, 2025, all March 2025 Pre-Funded Warrants have been exercised in full. The March 2025 Common Warrants becameexercisable upon stockholder approval on June 11, 2025 for a term of five years and have an exercise price of $1.00per share. Total cash issuance costs were $282,849including $199,863of placement fees, $56,844of legal fees, and $26,142of other costs.

 

Themodification date fair value of warrants modified during the three and six months ended June 30, 2025 and 2024 was determined using theBlack Scholes method, with the following assumptions used:

   For the Three Months Ended   For the Six Months Ended 
   June 30,   June 30, 
   2025   2024   2025   2024 
Fair value of common stock on date of modification   n/a    n/a   $0.98    n/a 
Risk free interest rate   n/a    n/a    4.09%   n/a 
Expected term (years)   n/a    n/a    5.3 years    n/a 
Expected volatility   n/a    n/a    125%   n/a 
Expected dividends   n/a    n/a    0.00%   n/a 

 

9

 

 

ZYVERSATHERAPEUTICS, INC.

 

Notesto Condensed Consolidated Financial Statements

 

Asummary of the warrant activity for the six months ended June 30, 2025, is presented below:

 

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Warrants   Price   In Years   Value 
                 
Outstanding, January 1, 2025   1,747,093   $59.59                
Issued [1]   2,105,265    1.00           
Repriced - Old [2]   (957,200)   2.06           
Repriced - New [2]   957,200    1.00           
Forfeited   (2,950)   12.50           
Exercised   -    -           
Outstanding, June 30, 2025   3,849,308   $27.25    4.81   $- 
                     
Exercisable, June 30, 2025   3,849,108   $27.16    4.88   $- 

 

[1] Warrants issued, outstanding, and exercisable exclude 2,105,265 March 2025 Pre-Funded Warrants with an exercise price of $0.0001.

 

[2] Warrants represent the reset of the exercise price of certain November 2024 warrants to purchase 957,200 shares of common stock from $2.06 to $1.00 per share.

 

Thefollowing table presents information related to stock warrants as of June 30, 2025:

 

Warrants Outstanding   Warrants Exercisable 
    Outstanding   Weighted Average   Exercisable 
Exercise   Number of   Remaining Life   Number of 
Price   Warrants   In Years   Warrants 
$1.00    3,062,465    4.94    3,062,465 
$2.06    679,800    4.94    679,800 
$12.50    4,050    3.45    4,050 
$47.50    20,347    3.70    20,347 
$57.75    19,965    3.02    19,965 
$350.00    27,551    2.83    27,551 
$700.00    13,944    2.45    13,944 
$1,760.50    200    -    - 
$2,415.00    3,651    2.45    3,651 
$4,025.00    17,335    2.45    17,335 
      3,849,308    4.88    3,849,108 

 

Note8 – Subsequent Events

 

WarrantInducement Offer

 

OnJuly 8, 2025, the Company entered into a warrant exercise inducement offer letter agreement (the “Inducement Letter”) witha holder (the “Holder”) of (i) outstanding Series A-2 common stock purchase warrants, as amended (the “Series A-2 Warrants”),exercisable for up to an aggregate of 957,200 shares of the Company’s common stock, and (ii) Series A-3 common stock purchase warrants(the “Series A-3 Warrants” and together with the Series A-2 Warrants, the “Existing Warrants”) exercisable forup to an aggregate of 2,105,265 shares of common stock, which warrants were originally issued by the Company on November 5, 2024 andMarch 5, 2024, respectively. The Existing Warrants had an exercise price of $1.00 per share.

 

TheHolder agreed to exercise the Existing Warrants for gross proceeds $2.05 million at a reduced exercise price of $0.67 per share in consideration of the Company’sagreement to issue the Holder new warrants to purchase up to a number of shares of common stock equal to 200% of the number of sharesof common stock issued pursuant to the Holder’s exercise of Existing Warrants, comprised of new Series A-4 warrants to purchaseup to 6,124,930 shares of common stock (the “Inducement Warrants”). The Inducement Warrants are exercisable upon stockholder approval at an exercise price of $0.67 per share and willexpire on the fifth anniversary of the date on which stockholder approval is obtained.

  

Nasdaq Stock Market LLC (“Nasdaq”)Delisting

 

On July 15, 2025, the Company received a determinationletter (the “Letter”) from Nasdaq indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to denythe Company’s request to continue our listing on The Nasdaq Capital Market. Trading of the Company’s common stock was suspendedat the open of trading on July 17, 2025. Our common stock began trading on the OTCQB® Venture Market on July 28, 2025, under thesymbol “ZVSA.”

10

 

 

ITEM2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Thefollowing discussion and analysis of the results of operations and financial condition of ZyVersa Therapeutics, Inc. (the “Company,”“we,” “us” or “our”) as of June 30, 2025 and for the three and six months ended June 30, 2025 and2024 should be read together with our unaudited condensed consolidated financial statements and the notes to those financial statementsthat are included elsewhere in this Quarterly Report on Form 10-Q. Additionally this discussion and analysis should be read togetherwith the Company’s audited financial statements and related disclosures as of December 31, 2024 and for the year then ended, whichare included in the Form 10-K (the “Annual Report”) filed with the Securities and Exchange Commission (“SEC”)on March 27, 2025. This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains statementsthat are forward-looking. These statements are based on current expectations and assumptions that are subject to risk, uncertaintiesand other factors. These statements are often identified by the use of words such as “may,” “will,” “expect,”“believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue,”and similar expressions or variations. Actual results could differ materially because of the factors discussed in “Risk Factors”in our Annual Report, and other factors that we may not know. Except as otherwise required by applicable law, we disclaim any duty toupdate any forward-looking statements, all of which are expressly qualified by the statements above, to reflect events or circumstancesafter the date of this Quarterly Report on Form 10-Q.

 

BusinessOverview

 

Weare a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugsfor patients with renal or inflammatory diseases with high unmet medical needs.

 

Ourrenal drug candidate, which we refer to as Cholesterol Efflux MediatorTM VAR 200 (2-hydroxypropyl-beta-cyclodextrin or “2HβCD”),is in development to treat multiple renal indications. The lead indication is focal segmental glomerulosclerosis (FSGS). Our anti-inflammatorydrug candidate, which we refer to as Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal IgG4 antibody targeting ASC in developmentto treat multiple inflammatory diseases. The lead indication is obesity with cardiometabolic comorbidities.

 

FinancialOperations Overview

 

Wehave not generated any revenue to date and have incurred significant operating losses. Our net losses were $4.5 million for the periodfrom January 1, 2025 through June 30, 2025, compared to $5.6 million for the period from January 1, 2024 through June 30, 2024. As ofJune 30, 2025, we had an accumulated deficit of approximately $117.1 million and cash of $0.1 million. We expect to continue to incursignificant expenses for the foreseeable future and to incur operating losses. We expect our expenses will increase in connection withour ongoing activities as we:

 

  progress development of VAR 200 and IC 100;
     
  prepare and file regulatory submissions;
     
  begin to manufacture our product candidates for clinical trials;
     
  hire additional research and development, finance, and general and administrative personnel;
     
  protect and defend our intellectual property; and
     
  meet the requirements of being a public company.

 

Wewill need additional financing to support our continuing operations. We will seek to fund our operations through public or private equityor debt financings or other sources, which may include government grants and collaborations with third parties. Adequate additional financingmay not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impacton our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieveprofitability, and we may never do so.

 

RecentDevelopments

 

OnJuly 15, 2025, we received a determination letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”)indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to deny our request to continue our listing on TheNasdaq Capital Market. Trading of our common stock was suspended at the open of trading on July 17, 2025. As a result of the suspension in trading and expecteddelisting, there may be a very limited market in which our shares are traded, our stockholders may find it difficult to sell their sharesof our common stock, and the trading price of our securities, if any, may be adversely affected. We applied for trading on the OTCQB® Venture Market (“OTCQB”) maintained by the OTC Markets Group Inc. to mitigate therisk of delisting from Nasdaq. Our application was approved on July 25, 2025, and our common stock began trading on OTCQB on July 28,2025, under the symbol “ZVSA.”

 

Componentsof Operating Results

 

Revenue

 

Sinceinception, we have not generated any revenue and do not expect to generate any revenue from the sale of products in the near future.If our development efforts for our product candidates are successful and result in regulatory approval, or if we enter into collaborationor license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments fromcollaboration or license agreements.

 

11

 

 

OperatingExpenses

 

Researchand Development Expenses

 

Researchand development expenses consist of costs incurred in the discovery and development of our product candidates, and primarily include:

 

  expenses incurred under third party agreements with contract research organizations (“CROs”), and investigative sites, that conducted or will conduct our clinical trials and a portion of our pre-clinical activities;
     
  costs of raw materials, as well as manufacturing cost of our materials used in clinical trials and other development testing;
     
  expenses, including salaries, stock-based compensation and benefits of employees engaged in research and development activities;
     
  costs of equipment, depreciation and other allocated expenses; and
     
  fees paid for contracted regulatory services as well as fees paid to regulatory authorities including the US Food and Drug Administration (the “FDA”) for review and approval of our product candidates.

 

Weexpense research and development costs as incurred. Costs for external development activities are recognized based on an evaluation ofthe progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are basedon the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statementsas prepaid expenses or accrued expenses.

 

Researchand development activities are central to our business model. We expect that our research and development expenses will continue to increasefor the foreseeable future as we continue preclinical and clinical development for our product candidates. As products enter later stagesof clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarilydue to the increased size and duration of later-stage clinical trials. Historically, our research and development costs have primarilyrelated to the development of VAR 200 and IC 100. As we advance VAR 200 and IC 100, as well as identify other potential product candidates,we will continue to allocate our direct external research and development costs to the products. We expect to fund our research and developmentexpenses from our current cash and cash equivalents and any future equity or debt financings, or other capital sources, including potentialcollaborations with other companies or other strategic transactions.

 

Thesuccessful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature,timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material netcash inflows may commence from our product candidates. This uncertainty is due to the numerous risks and uncertainties associated withthe duration and cost of clinical trials, which vary significantly over the life of a project resulting from many factors, including:

 

  the number of clinical sites included in the clinical trials;
     
  the length of time required to enroll suitable patients;
     
  the size of patient populations participating in the clinical trials;
     
  the number of doses a patient receives;
     
  the duration of patient follow-ups;
     
  the development state of the product candidates; and
     
  the efficacy and safety profile of the product candidates.

 

Ourexpenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals, and the expense of filing,prosecuting, defending and enforcing any patent claims or other intellectual property rights. We may never succeed in achieving regulatoryapproval for our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay ormodify clinical trials of our product candidates. A change in the outcome of any of these variables with respect to the development ofa product candidate could mean a significant change in the costs and timing associated with the development of that product candidate.For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currentlyanticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significantadditional financial resources and time on the completion of clinical development. Product commercialization will take several yearsand likely millions of dollars in development costs.

 

Generaland Administrative Expenses

 

Generaland administrative expenses consist primarily of salaries, stock-based compensation and related costs for our employees in administrative,executive and finance functions. General and administrative expenses also include professional fees for legal, accounting, audit, taxand consulting services, insurance, human resources, information technology, office, and travel expenses.

 

12

 

 

Weexpect that our general and administrative expenses will increase in the future as we increase our general and administrative headcountto support our continued research and development and potential commercialization of our product candidates. We also expect to incurincreased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax complianceservices, director and officer insurance, and investor and public relations costs.

 

Resultsof Operations

 

Aswe continue to explore commercial opportunities and partners in both U.S. and international markets, we remain attentive to evolvingglobal economic conditions, including uncertainties related to international trade policies, tariffs, and supply chain dynamics. Althoughthese factors have not had a material impact on our operations to day, future changes in trade regulations, tariff structures, or logisticalconstraints could influence the cost, availability, or timing of materials, services and other components associated with the developmentof our product candidates and manufacturing capabilities. We continue to monitor these developments closely to maintain operational efficiencyand help mitigate potential future impacts.

 

Comparisonof the three months ended June 30, 2025 and the three months ended June 30, 2024

 

Thefollowing table summarizes our results of operations for the three months ended June 30, 2025 and for the three months ended June 30,2024.

 

   For the Three Months Ended   Favorable 
   June 30,   (Unfavorable) 
(in thousands)  2025   2024   $ Change   % Change 
Operating expenses:                    
Research and development  $410   $709   $299    42.2%
General and administrative   1,634    2,045    411    20.1%
Total Operating Expenses   2,044    2,754    710    25.8%
                     
Loss from Operations   (2,044)   (2,754)   710    25.8%
                     
Other (Income) Expense, Net   167    -    (167)   (100.0%)
                     
Pre-tax net loss   (2,211)   (2,754)   543    19.7%
Income tax benefit   -    (10)   10    (100.0%)
Net loss  $(2,211)  $(2,764)  $553    20.0%

 

Researchand development expenses

 

Researchand development expenses were $0.4 million for the three months ended June 30, 2025, a decrease of $0.3 million or 42.2% from the threemonths ended June 30, 2024. The decrease is attributable to lower CRO fees of $0.1 million for VAR 200 and lower research and developmentconsultant costs of $0.1 million due to fewer consultants, lower pre-clinical costs of IC 100 of $0.1 million, partially offset by anincrease in VAR 200 manufacturing stability testing.

 

Generaland administrative expenses

 

Generaland administrative expenses were $1.6 million for the three months ended June 30, 2025, a decrease of $0.4 million or 20.1% from thethree months ended June 30, 2024. The decrease is primarily attributable to a decrease of $0.1 million due to lower director andofficer insurance premiums, a $0.1 million decrease in investor relations marketing expense, a $0.1 million decrease in professionalfees due to lower accounting and legal expense, and a decrease of $0.1 million in stock-based compensation expense due to optionsbecoming fully amortized in 2025, offset by a $0.1 million increase in public company costs due to additional costs for our annualshareholder meeting and Nasdaq hearings.

 

Other(Income) Expense, Net

 

Other(income) expense, net was $0.2 million for the three months ended June 30, 2025, an increase of $0.2 million from the three months endedJune 30, 2024. The increase in expense is primarily attributable to interest charged by a vendor for outstanding amounts owed.

 

13

 

 

Comparisonof the six months ended June 30, 2025 and the six months ended June 30, 2024

 

Thefollowing table summarizes our results of operations for the six months ended June 30, 2025 and for the six months ended June 30, 2024.

 

   For the Six Months Ended   Favorable 
   June 30,   (Unfavorable) 
(in thousands)  2025   2024   $ Change   % Change 
Operating expenses:                    
Research and development  $669   $1,222   $553    45.3%
General and administrative   3,520    4,358    838    19.2%
Total Operating Expenses   4,189    5,580    1,391    24.9%
                     
Loss from Operations   (4,189)   (5,580)   1,391    24.9%
                     
Other (Income) Expense, Net   279    -    (279)   (100.0%)
                     
Pre-tax net loss   (4,468)   (5,580)   1,112    19.9%
Income tax benefit   -    (10)   10    (100.0%)
Net loss  $(4,468)  $(5,590)  $1,122    20.1%

 

Researchand development expenses

 

Researchand development expenses were $0.7 million for the six months ended June 30, 2025, a decrease of $0.6 million or 45.3% from the six monthsended June 30, 2024. The decrease is attributable to lower CRO fees of $0.2 million for VAR 200 and lower research and development consultantcosts of $0.2 million due to fewer consultants, lower pre-clinical costs of IC 100 of $0.1 million, partially offset by an increase inVAR 200 manufacturing stability testing.

 

Generaland administrative expenses

 

Generaland administrative expenses were $3.5 million for the six months ended June 30, 2025, a decrease of $0.8 million or 19.2% from the sixmonths ended June 30, 2024. The decrease is primarily attributable to a decrease of $0.3 million due to lower director and officer insurancepremiums, a $0.2 million decrease in investor and public relations marketing expense, a $0.1 million decrease in professional fees dueto lower accounting and legal expense, and a decrease of $0.3 million in stock-based compensation expense due to options becoming fullyamortized in 2025, offset by a $0.1 million increase in legal patent fees for IC100 and public company costs due to additional costsfor our annual shareholder meeting and Nasdaq hearings.

 

Other(Income) Expense, Net

 

Other(income) expense, net was $0.3 million for the six months ended June 30, 2025, an increase of $0.3 million from the six months endedJune 30, 2024. The increase in expense is primarily attributable to interest charged by a vendor for outstanding amounts owed.

 

CashFlows

 

Thefollowing table summarizes our cash flows from operating and financing activities for the six months ended June 30, 2025 and for thesix months ended June 30, 2024:

 

    For the Six Months Ended June 30,     Increase  
(in thousands)   2025     2024     (decrease)  
Net cash provided by (used in)                        
Operating activities   $ (3,294 )   $ (5,691 )   $ 2,397  
Financing activities     1,835       2,673       (838 )
Net Decrease in Cash   $ (1,459 )   $ (3,018 )   $ 1,559  

  

14

 

 

CashFlows from Operating Activities

 

Netcash used in operating activities was approximately $3.3 million and approximately $5.7 million for the six months ended June 30, 2025and 2024, respectively. For the six months ended June 30, 2025 and for the six months ended June 30, 2024, the net cash used in operatingactivities was primarily attributable to the net loss of approximately $4.5 million and $5.6 million, respectively, offset by $0.3 millionand $0.5 million, respectively, of net non-cash expenses, and approximately $0.8 million and ($0.6) million, respectively, of cash generatedby (used in) the levels of operating assets and liabilities, respectively.

 

NetCash Provided By (Used In) Financing Activities

 

Netcash provided by financing activities was $1.8 million and $2.7 million for the six months ended June 30, 2025 and 2024, respectively.Cash provided by financing activities during the six months ended June 30, 2025 represented $2.0 million of proceeds from the privateplacement of warrants. This was partially offset by ($0.2) million in registration and issuance costs associated with warrant issuance.Cash provided by financing activities during the six months ended June 30, 2024 represented proceeds from the exercise of warrants

 

Liquidityand Capital Resources

 

Thefollowing table summarizes our total current assets, liabilities and working capital deficiency at June 30, 2025 and 2024, respectively:

 

   June 30,   December 31, 
(in thousands)  2025   2024 
Current Assets  $549   $1,716 
Current Liabilities  $12,690   $11,231 
Working Capital Deficiency  $(12,141)  $(9,515)

 

Sinceour inception in 2014 through June 30, 2025, we have not generated any revenue and have incurred significant operating losses and negativecash flows from our operations. Based on our current operating plan, we expect our cash of $0.1 million as of June 30, 2025 will onlybe sufficient to fund our operating expenses and capital expenditure requirements on a month-to-month basis. It is difficult to predictour spending for our product candidates prior to obtaining FDA approval. Moreover, changing circumstances may cause us to expend cashsignificantly faster than we currently anticipate, and we may need to spend more cash than currently expected because of circumstancesbeyond our control.

 

GoingConcern

 

Sinceinception we have been engaged in organizational activities, including raising capital and research and development activities. Wehave not generated revenues and have not yet achieved profitable operations, nor have we ever generated positive cash flow fromoperations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. We are subjectto those risks associated with any pre-clinical stage pharmaceutical company that has substantial expenditures for research anddevelopment. There can be no assurance that our research and development projects will be successful, that products developed willobtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, we operate in anenvironment of rapid technological change and are largely dependent on the services of our employees and consultants. Further, ourfuture operations are dependent on the success of our efforts to raise additional capital. These uncertainties raise substantialdoubt about our ability to continue as a going concern for 12 months after the issuance date of our financial statements. Theaccompanying financial statements have been prepared on a going concern basis. The financial statements do not include anyadjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts andclassification of liabilities that may result from the possible inability of us to continue as a going concern, which contemplatesthe continuation of operations, realization of assets and liquidation of liabilities in the ordinary course of business. We incurreda net loss of $4.5 million for the six months ended June 30, 2025 and had an accumulated deficit of $117.1 million on June 30, 2025.We anticipate incurring additional losses until such time, if ever, that we can generate significant revenue from our productcandidates currently in development. Our primary source of capital has been the issuance of debt and equity securities. We believethat current cash is only sufficient to fund operations and capital requirements on a month-to-month basis. Additional financingwill be needed by us to fund our operations, and to complete development of and to commercially develop our product candidates.There is no assurance that such financing will be available when needed or on acceptable terms.

 

ContractualObligations

 

Cashrequirements for our current liabilities as of June 30, 2025 include approximately $12.7 million for accounts payable and accrued expenses.Based on our current operating plan, we plan to satisfy the obligations identified below from our current cash balance and future financing.See Note 4, Accrued Expenses and Other Current Liabilities and Note 6, Commitments and Contingencies—Operating Leasesof the accompanying notes to the unaudited condensed consolidated financial statements included elsewhere in this report for more informationregarding our contractual obligations relating to our current liabilities and lease agreements, respectively.

 

FutureCapital Needs

 

Weexpect our cash on hand will enable us to make investments in our continued development of VAR 200 and IC 100 on a month-to-month basisas cash is available. We intend to raise additional capital in the future to fund continued development.

 

15

 

 

Weexpect to raise additional capital by issuing equity, equity-linked securities, or debt in subsequent offerings. If we are unable toraise additional capital on terms favorable to us, we may not have sufficient liquidity to execute our business strategy. We have variouswarrants outstanding that can be exercised for our common stock, many of which must be exercised in exchange for cash paid to us by theholders of such warrants. If the market price of our common stock is less than the exercise price of a holder’s warrants, it isunlikely that holders will exercise their warrants. As such, we do not expect to receive significant proceeds in the near term from theexercise of most of our warrants based on the current market price of our common stock and the exercise prices of such warrants.

 

Ourpolicy is to invest any cash exceeding our immediate requirements in investments designed to preserve the principal balance and provideliquidity while producing a modest return on investment. Accordingly, our excess cash equivalents will be invested primarily in moneymarket funds.

 

Weexpect to continue to incur substantial additional operating losses for at least the next several years as we continue to develop ourproduct candidates and seek marketing approval and, subject to obtaining such approval, the eventual commercialization of our productcandidates. If we obtain marketing approval for our product candidates, we will incur significant sales, marketing and outsourced manufacturingexpenses. In addition, we expect to incur additional expenses to add operational, financial, and information systems and personnel, tosupport our planned product development efforts, among other initiatives. We also expect to incur significant costs to comply with corporategovernance, internal controls, and similar requirements applicable to public companies.

 

Ourfuture use of operating cash and capital requirements will depend on many forward-looking factors, including the following:

 

  the initiation, progress, timing, costs and results of clinical trials for our product candidates;
     
  the clinical development plans we establish for each product candidate;
     
  the number and characteristics of product candidates that we develop or may in-license;

 

  the terms of any collaboration agreements we may choose to execute;
     
  the outcome, timing and cost of meeting regulatory requirements established by the FDA or other comparable foreign regulatory authorities;
     
  the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;
     
  the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us;
     
  the cost and timing of the implementation of commercial scale manufacturing activities; and
     
  the cost of establishing, or outsourcing, sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own.

 

Tocontinue to grow our business over the longer term, we plan to commit substantial resources to research and development, clinical trialsof our product candidates, and other operations and potential product acquisitions and in-licensing. We have evaluated and expect tocontinue to evaluate a wide array of strategic transactions as part of our plan to acquire or in-license and develop additional productsand product candidates to augment our internal development pipeline. Strategic transaction opportunities that we may pursue could materiallyaffect our liquidity and capital resources and may require us to incur additional indebtedness, seek equity capital or both. In addition,we may pursue development, acquisition or in-licensing of approved or development products in new or existing therapeutic areas or continuethe expansion of our existing operations. Accordingly, we expect to continue to opportunistically seek access to additional capital tolicense or acquire additional products, product candidates or companies to expand our operations, or for general corporate purposes.Strategic transactions may require us to raise additional capital through one or more public or private debt or equity financings orcould be structured as a collaboration or partnering arrangement. We have no arrangements, agreements, or understandings in place atthe present time to enter into any acquisition, in-licensing or similar strategic business transaction. In addition, we continue to evaluatecommercial collaborations and strategic relationships with established pharmaceutical companies, which would provide us with more immediateaccess to marketing, sales, market access and distribution infrastructure.

 

Ifwe raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, wouldresult in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability totake specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additionalequity that we raise may contain terms, such as liquidation and other preferences that are not favorable to us or our existing stockholders.If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuablerights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us.

 

JOBSAct Accounting Election

 

ZyVersais an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. The JOBSAct permits companies with emerging growth company status to take advantage of an extended transition period to comply with new or revisedaccounting standards, delaying the adoption of these accounting standards until they would apply to private companies. ZyVersa expectsto use this extended transition period to enable it to comply with new or revised accounting standards that have different effectivedates for public and private companies until the earlier of the date the Company (1) is no longer an emerging growth company or (2) affirmativelyand irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not becomparable to companies that comply with the new or revised accounting standards as of public company effective dates.

 

16

 

 

Inaddition, the Company intends to rely on the other exemptions and reduced reporting requirements provided by the JOBS Act.

 

Off-BalanceSheet Arrangements

 

Thereare no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or futureeffect on financial conditions, changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expendituresor capital resources that is material to stockholders.

 

CriticalAccounting Estimates

 

Weprepare our condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles, which requireour management to make estimates that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilitiesat the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent thatthere are material differences between these estimates and actual results, our financial condition or results of operations would beaffected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking accountof our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.

 

Weconsider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that werehighly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur fromperiod to period or use of different estimates that we reasonably could have used in the current period, would have a material impacton our financial condition or results of operations. Our critical accounting estimates are described below.

 

Impairmentof Long-Lived Assets and Goodwill

 

TheCompany reviews for the impairment of long-lived assets and goodwill whenever events or changes in circumstances indicate that the carryingamount of an asset may not be recoverable. The Company measures the carrying amount of the asset against the estimated undiscounted futurecash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset beingevaluated, an impairment loss would be recognized for the amount by which the carrying value of the asset exceeds its fair value. Theevaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated.These assumptions require significant judgment and actual results may differ from assumed and estimated amounts.

 

Thereare other items within our financial statements that require estimation but are not deemed critical, as defined above.

 

ITEM3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Notapplicable.

 

ITEM4. CONTROLS AND PROCEDURES

 

DisclosureControls and Procedures

 

Disclosurecontrols and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in ourreports filed or submitted under the Exchange Act, is recorded, processed, summarized and reported within the time periods specifiedin the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designedto ensure that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicatedto management, including our Chief Executive Officer and Chief Financial Officer (who serve as our Principal Executive Officer and PrincipalFinancial and Accounting Officer, respectively), to allow timely decisions regarding required disclosure.

 

Asrequired by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluationof the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2025. Based upon their evaluation,our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e)and 15d-15(e) under the Exchange Act) were effective.

 

Changesin Internal Control over Financial Reporting

 

Therewere no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the ExchangeAct) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internalcontrol over financial reporting.

 

InherentLimitations of the Effectiveness of Controls

 

Managementdoes not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect allerrors and fraud. A control system, no matter how well designed and operated, is based upon certain assumptions and can provide onlyreasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurancethat misstatements due to errors or fraud will not occur or that all control issues and instances of fraud, if any, within the Companyhave been detected.

 

17

 

 

PARTII – OTHER INFORMATION

 

ITEM1. LEGAL PROCEEDINGS.

 

None.

 

ITEM1A. RISK FACTORS.

 

Our common stock could become subject to theSEC’s penny stock rules, which may cause broker-dealers to experience difficulty in completing transactions in our common stock,limiting a stockholder’s ability to buy and sell our common stock.

 

The SEC has adopted Rule 15g-9,which generally defines “penny stock” to be any equity security, not listed on a national exchange, that has a market priceless than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions, such as if the issuer of thesecurity has net tangible assets in excess of $2.0 million. The market price of our common stock is less than $5.00, and, effective July17, 2025, Nasdaq suspended trading in our common stock and started the process to delist our common stock from The Nasdaq Capital Marketdue to the Company’s ongoing failure to comply with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Ourcommon stock is presently exempt from being considered a “penny stock,” regardless of whether Nasdaq ultimately delists ourcommon stock from its exchange, because our net tangible assets exceed $2.0 million. As of December 31, 2024, we had approximately $[8.5]million in net tangible assets. However, we cannot guarantee that we will be able to continue to qualify for this exemption, or any otheravailable exemption from the definition of “penny stock.”

 

If our securities become subjectto the penny stock rules, broker-dealers who sell to persons other than established customers and “accredited investors” willbe subject to additional sales practice requirements. The term “accredited investor” generally refers to institutions withassets in excess of $5,000,000 or individuals with a net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000jointly with their spouse. The penny stock rules require a broker-dealer, prior to a transaction in penny stock not otherwise exempt fromthe rules, to deliver a standardized risk disclosure document in a form prepared by the SEC, which provides information about penny stocksand the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offerquotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account statementsshowing the market value of each penny stock held in the customer’s account. The bid and offer quotations, and the broker-dealerand salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and mustbe given to the customer in writing before or with the customer’s confirmation. In addition, the penny stock rules require thatprior to a transaction in penny stock not otherwise exempt from these rules, the broker-dealer must make a special written determinationthat the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction.These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for securities subjectto these penny stock rules and affect the ability of broker-dealers to trade our securities. As a result of the foregoing requirements,the marketability of our common stock may be further limited.

 

If our common stock is deemed “penny stock,”broker-dealers trading in our securities may be subject to additional sales practice requirements adopted by the Financial Industry RegulatoryAuthority (“FINRA”), which may also limit a stockholder’s ability to buy and sell our common stock.

 

In addition to the penny stockrules described above, FINRA has adopted rules that require broker-dealers to have reasonable grounds for believing that an investmentis suitable for a customer before recommending that investment to the customer. Prior to recommending speculative low priced securitiesto their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financialstatus, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is ahigh probability that speculative low priced securities will not be suitable for at least some customers. If our common stock is deemed“penny stock,” FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our securities,which may limit your ability to buy and sell our common stock and have an adverse effect on the market for our shares.

 

Our common stock may be delisted from Nasdaq,and there can be no assurance that it will trade on a national exchange again.

 

Effective July 17, 2025, Nasdaqsuspended trading in our common stock and started the process to delist our common stock from The Nasdaq Capital Market due to the Company’songoing failure to comply with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Our common stock is currently quotedon the OTCQB under the ticker symbol “ZVSA.”

 

Changes in tax laws and regulations or in ouroperations may impact our effective tax rate and may adversely affect our business, financial condition and operating results.

 

Changesin tax laws in any jurisdiction in which we operate, or adverse outcomes from any tax audits that we may be subject to in any such jurisdictions,could result in an unfavorable change in our effective tax rate in the future, which could adversely affect our business, financial condition,and operating results. For example, the Tax Reform Act of 2025 was signed into law on July 4, 2025. The Tax Reform Act of 2025 containsnumerous tax provisions that we are currently in the process of evaluating, and which may significantly affect our business or financialcondition. The recent changes under the Tax Reform Act of 2025 include tax rate extensions and changes to the business interest deductionlimitation, the expensing of domestic research and development expenditures (in contrast to the continued capitalization and amortizationof foreign research and development expenditures), the bonus depreciation deduction rules and the international tax framework. Regulatoryguidance under the Tax Reform Act of 2025 and additional tax-related legislation is and continues to be forthcoming, and the overallimpact of these changes is uncertain and may adversely affect our business, operating results and financial condition.

 

ITEM2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None.

 

ITEM3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM4. MINE SAFETY DISCLOSURES.

 

Notapplicable.

 

ITEM5. OTHER INFORMATION.

 

InsiderTrading Plans

 

Duringthe six months ended June 30, 2025, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted,modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as eachterm is defined in Item 408(a) of Regulation S-K.

 

18

 

 

ITEM6. EXHIBITS.

 

Exhibit   Description
3.1   Second Amended and Restated Certificate of Incorporation of ZyVersa Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 10-Q filed with the SEC on August 9, 2024).
3.2   Second Amended and Restated Bylaws of ZyVersa Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2022).
3.3   Certificate of Designation relating to the Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2022).
4.1   Form of Series A-4 Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 9, 2025).
10.1   Form of Equity Purchase Agreement, dated June 24, 2025, by and between ZyVersa Therapeutics, Inc. and Williamsburg Venture Holdings, LLC (incorporated by reference to Exhibit 10.1 to the Company Current Report on Form 8-K filed with the SEC on June 25, 2025).
10.2   Form of Registration Rights Agreement, dated June 24, 2025, by and between ZyVersa Therapeutics, Inc. and Williamsburg Venture Holdings, LLC (incorporated by reference to Exhibit 10.2 to the Company Current Report on Form 8-K filed with the SEC on June 25, 2025).
10.3   Inducement Letter, dated July 8, 2025 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 9, 2025).
10.4   Financial Advisory Agreement, dated July 8, 2025 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on July 9, 2025).
31.1*   Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
31.2*   Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
32.1**   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350.
101.INS**   XBRL Inline Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH*   Inline XBRL Taxonomy Extension Schema Document.
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibits 101).

 

* Filed herewith.
** Furnished herewith.

 

19

 

 

SIGNATURES

 

Pursuantto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this quarterly report to be signed on itsbehalf by the undersigned hereunto duly authorized.

 

Dated: August 13, 2025 By: /s/ Stephen C, Glover
    Stephen C. Glover
    Chief Executive Officer
    (Principal Executive Officer)
     
Dated: August 13, 2025 By: /s/ Peter Wolfe
    Peter Wolfe
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

20

 

 

Exhibit31.1

Certificationof

PrincipalExecutive Officer

ofZYVERSA THERAPEUTICS, INC.

Pursuantto Section 302 of the Sarbanes-Oxley Act of 2002

 

I,Stephen C. Glover, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of ZyVersa Therapeutics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
   
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this quarterly report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):
   
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: August 13, 2025 By: /s/ Stephen C. Glover
    Stephen C. Glover
    Chief Executive Officer
    (Principal Executive Officer)

 

 

 

 

Exhibit31.2

 

Certificationof

PrincipalExecutive Officer

ofZYVERSA THERAPEUTICS, INC.

Pursuantto Section 302 of the Sarbanes-Oxley Act of 2002

 

I,Peter Wolfe, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of ZyVersa Therapeutics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
   
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this quarterly report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):
   
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: August 13, 2025 By: /s/ Peter Wolfe
    Peter Wolfe
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

 

 

Exhibit32.1

 

CERTIFICATIONPURSUANT TO 18 U.S.C. SECTION 1350,

ASADOPTED PURSUANT TO

SECTION906 OF THE SARBANES-OXLEY ACT OF 2002

 

Inconnection with the Quarterly Report of ZyVersa Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended June30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersignedofficers of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of2002, that, to such officer’s knowledge:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operationsof the Company as of the dates and for the periods expressed in the Report.

 

Dated:  August 13, 2025 By: /s/ Stephen C. Glover
    Stephen C. Glover
    Chief Executive Officer
    (Principal Executive Officer)
     
Dated:  August 13, 2025 By: /s/ Peter Wolfe
    Peter Wolfe
    Chief Financial Officer
    (Principal Financial and Accounting Officer)